+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Physiological mouse brain Abeta levels are not related to the phosphorylation state of threonine-668 of Alzheimer's APP



Physiological mouse brain Abeta levels are not related to the phosphorylation state of threonine-668 of Alzheimer's APP



Plos One 1: E51



Amyloid-beta peptide species ending at positions 40 and 42 (Abeta40, Abeta42) are generated by the proteolytic processing of the Alzheimer's amyloid precursor protein (APP). Abeta peptides accumulate in the brain early in the course of Alzheimer's disease (AD), especially Abeta42. The cytoplasmic domain of APP regulates intracellular trafficking and metabolism of APP and its carboxyl-terminal fragments (CTFalpha, CTFbeta). The role of protein phosphorylation in general, and that of the phosphorylation state of APP at threonine-668 (Thr668) in particular, has been investigated in detail by several laboratories (including our own). Some investigators have recently proposed that the phosphorylation state of Thr668 plays a pivotal role in governing brain Abeta levels, prompting the current study. In order to evaluate whether the phosphorylation state of Thr668 controlled brain Abeta levels, we studied the levels and subcellular distributions of holoAPP, sAPPalpha, sAPPbeta, CTFalpha, CTFbeta, Abeta40 and Abeta42 in brains from "knock-in" mice in which a non-phosphorylatable alanyl residue had been substituted at position 668, replacing the threonyl residue present in the wild-type protein. The levels and subcellular distributions of holoAPP, sAPPalpha, sAPPbeta, CTFalpha, CTFbeta, Abeta40 and Abeta42 in the brains of Thr668Ala mutant mice were identical to those observed in wild-type mice. These results indicate that, despite speculation to the contrary, the phosphorylation state of APP at Thr668 does not play an obvious role in governing the physiological levels of brain Abeta40 or Abeta42 in vivo.

(PDF emailed within 0-6 h: $19.90)

Accession: 049925371

Download citation: RISBibTeXText

PMID: 17183681

DOI: 10.1371/journal.pone.0000051


Related references

Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Human Molecular Genetics 13(17): 1959-1968, 2004

Dietary composition modulates brain mass and solubilizable Abeta levels in a mouse model of aggressive Alzheimer's amyloid pathology. Molecular Neurodegeneration 4: 40, 2009

Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. Faseb Journal 21(9): 2135-2148, 2007

A comparative analysis of brain and plasma Abeta levels in eight common non-transgenic mouse strains: validation of a specific immunoassay for total rodent Abeta. Current Alzheimer Research 4(3): 297-303, 2007

Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Molecular and Cellular Neurosciences 15(2): 183-198, 2000

Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. Journal of Neuroscience 31(6): 2313-2320, 2011

Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. Journal of Neuroscience 26(18): 4717-4728, 2006

Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model. Febs Letters 579(30): 6737-6744, 2005

Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease. Histology and Histopathology 23(1): 67-76, 2007

Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. Neurobiology of Disease 15(2): 351-360, 2004

Amyloid Abeta levels in Alzheimer's disease - A diagnostic tool and the key to understanding the natural history of Abeta?. Journal of Alzheimer's Disease 3(3): 305-312, 2002

Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochemical and Biophysical Research Communications 252(3): 711-715, 1998

MMP-2, -3 and -9 levels and activity are not related to Abeta load in the frontal cortex in Alzheimer's disease. Neuropathology and Applied Neurobiology 34(2): 205-215, 2007

Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease. Psychopharmacology 230(2): 279-289, 2014

Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. Molecular Pharmaceutics 8(1): 280-285, 2011